Crushed cancer pill study aims to help kids who Can't swallow tablets
NCT ID NCT06131801
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure the liquid form works properly. This is a knowledge-gathering study, not a test of whether the drug cures the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Children's Hospital Colorado
RECRUITINGAurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can an immune booster outsmart brain lymphoma?
- Can a Tumor's DNA guide better cancer care for kids?
- A shot at safer CAR t: early brain protection for lymphoma patients?